Camrelizumab
Camrelizumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. It is known to target programmed cell death protein 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
661 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 7 | 42 | 11 | 1 | 28 | 79 |
| Non-small-cell lung carcinoma | D002289 | — | — | 6 | 31 | 8 | 1 | 10 | 52 |
| Lung neoplasms | D008175 | — | C34.90 | 4 | 20 | 4 | 1 | 9 | 35 |
| Small cell lung carcinoma | D055752 | — | — | — | 5 | 1 | 1 | 1 | 8 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 13 | 79 | 15 | — | 25 | 118 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 10 | 56 | 16 | — | 35 | 104 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 6 | 37 | 4 | — | 5 | 47 |
| Esophageal squamous cell carcinoma | D000077277 | — | — | 6 | 30 | 6 | — | 8 | 44 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 7 | 31 | 9 | — | — | 42 |
| Triple negative breast neoplasms | D064726 | — | — | 6 | 27 | 9 | — | 1 | 37 |
| Esophageal neoplasms | D004938 | — | C15 | 3 | 24 | 6 | — | 7 | 37 |
| Squamous cell carcinoma | D002294 | — | — | 4 | 28 | 2 | — | 5 | 36 |
| Nasopharyngeal carcinoma | D000077274 | — | — | 1 | 23 | 12 | — | — | 35 |
| Neoplasms | D009369 | — | C80 | 11 | 20 | 3 | — | 3 | 32 |
Show 29 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | — | 6 | 16 | — | — | 4 | 21 |
| Cholangiocarcinoma | D018281 | — | C22.1 | — | 10 | — | — | 2 | 12 |
| Biliary tract neoplasms | D001661 | — | C24.9 | 2 | 11 | — | — | — | 11 |
| Sarcoma | D012509 | — | — | 1 | 10 | — | — | — | 11 |
| Osteosarcoma | D012516 | — | — | 1 | 5 | — | — | 2 | 7 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | — | 4 | — | — | 2 | 6 |
| Head and neck neoplasms | D006258 | — | — | 2 | 4 | — | — | — | 5 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | 2 | 3 | — | — | — | 5 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | — | 4 | — | — | — | 4 |
| T-cell lymphoma peripheral | D016411 | — | — | 2 | 4 | — | — | — | 4 |
Show 73 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematologic neoplasms | D019337 | — | — | 1 | — | — | — | — | 1 |
| Hyperbaric oxygenation | D006931 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | — | — | — | 2 | 2 |
| Thrombosis | D013927 | — | — | — | — | — | — | 2 | 2 |
| Catheter ablation | D017115 | — | — | — | — | — | — | 2 | 2 |
| Stents | D015607 | — | — | — | — | — | — | 1 | 1 |
| Venous thrombosis | D020246 | — | I82.40 | — | — | — | — | 1 | 1 |
| Clear cell adenocarcinoma | D018262 | — | — | — | — | — | — | 1 | 1 |
| Adenomyoepithelioma | D055331 | — | — | — | — | — | — | 1 | 1 |
| Acute kidney injury | D058186 | — | N17 | — | — | — | — | 1 | 1 |
| Male breast neoplasms | D018567 | — | — | — | — | — | — | 1 | 1 |
| Gastrointestinal microbiome | D000069196 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Camrelizumab |
| INN | camrelizumab |
| Description | Camrelizumab (SHR-1210) (INN) is an anti-PD-1 immune checkpoint inhibitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | 7CU5 |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297715 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 73096E137E (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
PDCD1
PDCD1
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,752 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
502 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use